Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines.
Apoptosis
/ drug effects
Cell Proliferation
/ drug effects
Cyclin D1
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ drug effects
HeLa Cells
Humans
Hypoglycemic Agents
/ pharmacology
Metformin
/ pharmacology
Signal Transduction
Tumor Suppressor Protein p53
/ genetics
Uterine Cervical Neoplasms
/ drug therapy
Apoptosis
Cyclin D1
HeLa cell
Metformin
p53
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
22
05
2018
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
19
12
2019
Statut:
epublish
Résumé
Background: Cervical cancer is one of the most prevalent gynecological cancers worldwide and contributes in high
mortality of Indonesian women. The efficacy of chemotherapy as a standart therapy for cervical cancer decreases because
it frequenly rises adverse effects. Recent studies have found that metformin has a potential anticancer effect mostly
through reduction of cyclin expression and activation of Activated Adenosine Monophosphate Kinase (AMPK). This
study aimed to investigate the effect of metfomin on expression of cyclin D1 and p53 and apoptosis in HeLa cancer cell
line. Methods: HeLa cells were treated with various doses of metformin and doxorubicin as a positive control. Cytotoxic
effect of metformin was determined using the MTT assay. Immunocytochemistry was used to assess cyclin D1 and p53
expression and apoptosis levels of treated HeLa cells were analyzed using flowcytometry. Data of cyclin D1 expression
was statistically analyzed using the Kruskal-Wallis test followed by the Tamhane test, whilst ANOVA and Tukey post
Hoc tests were used to analyze data of p53 and apoptosis level. The significant value was p< 0.05. Results: Metformin
was able to inhibit proliferation of HeLa cells with IC50 60 mM. HeLa cells treated with 60 and 120 mM metformin
had lower cyclin D1 expression than HeLa cells treated without metformin and reached a significant difference (p=
0.001). Moreover, 30 mM or higher doses of metformin increase significantly p53 expression (p< 0.001). Induction of
apoptosis was observed in HeLa cells treated with all doses of metformin and reached statistically difference (p= 0.04
and p < 0.001). Conclusion: Metformin can modulate cyclin D1 and p53 expression in HeLa cancer cell line, leading
to inhibition of cell proliferation and induction of apoptosis. Other cyclin family members, CDK inhibitors and AMPK
signaling should be further investigated in order to know mechanism of metformin action.
Identifiants
pubmed: 31244286
doi: 10.31557/APJCP.2019.20.6.1667
pmc: PMC7021606
pii:
doi:
Substances chimiques
CCND1 protein, human
0
Hypoglycemic Agents
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Cyclin D1
136601-57-5
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1667-1673Références
Mini Rev Med Chem. 2008 Nov;8(13):1343-54
pubmed: 18991752
BMC Biol. 2013 Apr 15;11:36
pubmed: 23587167
Anticancer Res. 2009 Jul;29(7):2665-9
pubmed: 19596943
Am J Health Syst Pharm. 2008 Nov 15;65(22):2105-12
pubmed: 18997137
Gynecol Oncol. 2012 Oct;127(1):249-55
pubmed: 22735790
Cancer Res. 2007 Nov 15;67(22):10804-12
pubmed: 18006825
Cancers (Basel). 2011 Mar 15;3(1):1351-71
pubmed: 24212665
BMC Complement Altern Med. 2011 Nov 09;11:111
pubmed: 22070864
Mol Cell. 2005 Apr 29;18(3):283-93
pubmed: 15866171
Drug Des Devel Ther. 2016 Jun 07;10:1885-95
pubmed: 27354763
J Transl Med. 2011 May 24;9:76
pubmed: 21609436
Cell Metab. 2013 Jan 8;17(1):113-24
pubmed: 23274086
Oncogene. 2015 Jul;34(27):3605-16
pubmed: 25263447
J Mol Signal. 2008 Dec 01;3:18
pubmed: 19046439
Oncogene. 2008 Jun 5;27(25):3576-86
pubmed: 18212742
Oncogene. 2012 Jan 12;31(2):173-86
pubmed: 21765464
Asian Pac J Cancer Prev. 2014;15(14):5781-5
pubmed: 25081701
BMC Cancer. 2012 Nov 14;12:517
pubmed: 23151022
Anat Rec (Hoboken). 2011 Aug;294(8):1337-43
pubmed: 21717584
Cell Biosci. 2012 Jan 13;2:2
pubmed: 22244155
Cancer Metastasis Rev. 2001;20(1-2):63-8
pubmed: 11831649
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5523-7
pubmed: 1648218
Cancer Res. 2011 May 1;71(9):3196-201
pubmed: 21415163
Anticancer Res. 2006 Nov-Dec;26(6B):4125-9
pubmed: 17201123
Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1839-48
pubmed: 23589839
Nature. 2016 Jan 28;529(7587):541-5
pubmed: 26789255
Mol Cell Biol. 1994 Mar;14(3):2066-76
pubmed: 8114738
Eur J Pharmacol. 2011 Oct 15;668(3):373-82
pubmed: 21806981
Diabetes Care. 2010 Jun;33(6):1304-8
pubmed: 20299480
Hormones (Athens). 2011 Jan-Mar;10(1):5-15
pubmed: 21349801
CA Cancer J Clin. 2005 May-Jun;55(3):178-94
pubmed: 15890640
J Anat. 2004 Nov;205(5):405-12
pubmed: 15575889
Oncogene. 2011 Jan 20;30(3):346-55
pubmed: 20871630
Cancer Res. 2006 Nov 1;66(21):10269-73
pubmed: 17062558
Oncogene. 1998 Dec 24;17(25):3287-99
pubmed: 9916991
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cell Cycle. 2009 Mar 15;8(6):909-15
pubmed: 19221498
Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):101-11
pubmed: 21119073
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35
pubmed: 14985505
Gynecol Oncol. 2011 Jun 1;121(3):492-8
pubmed: 21388661
Gynecol Oncol. 2012 May;125(2):458-69
pubmed: 22252099
Cancer Res. 2010 Mar 15;70(6):2465-75
pubmed: 20215500
Int J Hematol Oncol Stem Cell Res. 2014 Jul 1;8(3):12-9
pubmed: 25642303
Clin Cancer Res. 2011 Jun 15;17(12):3993-4005
pubmed: 21543517
Trends Endocrinol Metab. 2013 Sep;24(9):469-80
pubmed: 23773243
Cell Cycle. 2012 Apr 1;11(7):1374-82
pubmed: 22421144